Press ESC to close

Opti-GuideOpti-Guide

Johnson & Johnson to Acquire Ollin Biosciences to Expand Ophthalmology Portfolio

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences (“Blackstone”) to support the Phase 3 clinical advancement of OLN324, contingent upon acquisition close.

With this agreement, Johnson & Johnson would add to its pipeline OLN324, an investigational bispecific antibody designed to target two key pathways in retinal diseases, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). OLN324 is a next-generation antibody with high Ang2 potency and a small protein format (minibody) that could enable improved control of retinal fluid. It is being developed for conditions including wet age-related macular degeneration (AMD) and diabetic macular edema, which together affect more than 40 million people worldwide and are leading causes of vision loss.1,2,3

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson. “The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”

Johnson & Johnson’s combination of scientific, development and commercial capabilities position the Company to advance OLN324 and build on Ollin’s promising science. The proposed acquisition would strengthen Johnson & Johnson’s leadership in ophthalmology and its commitment to preserve, restore, and enhance vision for millions of people worldwide.

Transaction and financial details

Key terms of the proposed acquisition and related development funding arrangement include:

  • Acquisition of Ollin:
    • Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments up to approximately $1.125
    • The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.
  • Development funding with Blackstone:
    • Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324.
    • In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single digit royalties.

The accounting treatment will be communicated on or before the close of the transaction.

 

 

References:
1 Wong TY, Tan TE. Invest Ophthalmol Vis Sci. 2023;64(15):47. doi:10.1167/iovs.64.15.47
2 Macular Degeneration Association. “What is Macular Degeneration?” Accessed November 13, 2026.
3 Apte RS. N Engl J Med. 2021;385(6):539-547. doi:10.1056/NEJMcp2102061.

Opti-News Newsletter
line opti
Receive the latest Canadian eyecare news, weekly.
Trusted by +8,000 subscribers.
Auto close in 7 seconds